CHMP position statement on Creutzfeldt-Jakob disease and plasma-derived and urine-derived medicinal products

We have adopted this International Scientific Guideline - EMA/CHMP/BWP/303353/2010.

Last updated

20 February 2025

About this guideline

Overseas adoption date: 23 June 2011

Categories: Biologicals| Active substance | Plasma-derived medicinal products

TGA annotations: Nil

Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.

Product types

Topics